Researchers at Genentech have locally blocked lung inflammation in a mouse model for asthma by administration of an inhalable JAK1 inhibitor.
The European Investment Bank (EIB) has lent antiinfectives company F2G Biotech Ltd €24m for antifungal research and innovation under the InnovFin Infectious Diseases Finance Facility (IDFF).
Researchers at Cancer UK have slowed down tumour growth by simply feeding mice that carry human tumour xenografts with mannose instead of glucose.
Researchers at IRB Barcelona report that tumours may become more aggressive following treatment with drugs that inhibit epigenetic factors.
Inflammosome inhibitor specialist Inflazome Ltd has raised €40m in a Series B financing led by Forbion with co-investors Longitude Capital, Novartis Venture Fund and Fountain Healthcare Partners.
The EU Commission’s Chief Scientific Advisors urge the Commission to revise the EU’s GMO Directive in order to harness gene editing.
Boehringer Ingelheim and Epizyme, Inc. will collaborate in the field of small molecule cancer drugs that target unaddressed epigenetic targets within the helicase and histone acetyltransferase families.
Researchers at University of Göttingen, Germany, have identified nerve excitability of motor nerve cells trigger restless legs syndrome.
AstraZeneca plc has sold US rights to its off-patent blockbuster drug Synagis (palivizumab) and a 50% share on future earnings of its Phase II RSV-prophylactic follow-on antibody MEDI8897 to Swedish Orphan Biovitrum AB.
Swiss Amal Therapeutics S.A. (Geneva) has raised €21.2m in a series B follow-up financing.